A detailed history of Creative Planning transactions in Novo Cure LTD stock. As of the latest transaction made, Creative Planning holds 15,545 shares of NVCR stock, worth $498,994. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,545
Previous 15,209 2.21%
Holding current value
$498,994
Previous $260,000 6.92%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$15.61 - $23.34 $5,244 - $7,842
336 Added 2.21%
15,545 $242,000
Q2 2024

Aug 15, 2024

BUY
$11.83 - $24.05 $60,995 - $124,001
5,156 Added 51.29%
15,209 $260,000
Q1 2024

May 10, 2024

BUY
$12.42 - $17.29 $124,858 - $173,816
10,053 New
10,053 $157,000
Q2 2023

Jul 21, 2023

SELL
$40.29 - $82.51 $19,742 - $40,429
-490 Reduced 7.52%
6,024 $249,000
Q1 2023

May 15, 2023

BUY
$56.44 - $118.81 $11,795 - $24,831
209 Added 3.31%
6,514 $391,000
Q4 2022

Feb 10, 2023

BUY
$63.98 - $85.37 $403,393 - $538,257
6,305 New
6,305 $462,000
Q2 2022

Aug 15, 2022

SELL
$56.6 - $89.9 $1,698 - $2,697
-30 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$60.15 - $84.52 $1,804 - $2,535
30 New
30 $2,000
Q3 2021

Nov 10, 2021

SELL
$116.17 - $194.55 $155,783 - $260,891
-1,341 Closed
0 $0
Q2 2021

Aug 04, 2021

SELL
$130.4 - $225.58 $67,156 - $116,173
-515 Reduced 27.75%
1,341 $297,000
Q1 2021

Apr 30, 2021

SELL
$124.11 - $190.17 $487,876 - $747,558
-3,931 Reduced 67.93%
1,856 $245,000
Q4 2020

Jan 29, 2021

BUY
$112.16 - $174.14 $649,069 - $1.01 Million
5,787 New
5,787 $1 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.37B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.